Clinical Trial Update: A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) [Phase 1]

View source ↗

Summary

Phase 1 trial of TAK-659 as a single agent in adult East Asian participants with various non-Hodgkin lymphoma subtypes was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• TAK-659 (TAK-659)

Snippet

Sponsor: Calithera Biosciences, Inc | Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Marginal Zone | Phase 1 | Status: TERMINATED | Results posted: 2021-09-14